Mezigdomide (MEZI) in novel targeted combinations for relapsed/refractory multiple myeloma (RRMM): updated results from the phase 1/2 CA057-003 trial
Costa, L. Schjesvold, F. Popat, R. Siegel, D. Usmani, S. Al, S. A. Chu, M. Hartley-Brown, M. Bahlis, N. Oriol, A.
Costa, L.
Schjesvold, F.
Popat, R.
Siegel, D.
Usmani, S.
Al, S. A.
Chu, M.
Hartley-Brown, M.
Bahlis, N.
Oriol, A.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2025
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Costa L, Schjesvold F, Popat R, Siegel D, Usmani S, Al SA, et al. Mezigdomide (MEZI) in novel targeted combinations for relapsed/refractory multiple myeloma (RRMM): updated results from the phase 1/2 CA057-003 trial. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2025 SEP;25. PubMed PMID: WOS:001592850100078. English.